Featured Insights

  1. Why CMC Is A Key Sticking Point For CGTs And How To Meet FDA Expectations 10/2/2025

    FDA scrutiny of CMC for cell and gene therapies is high. Learn common pitfalls—like issues with potency and comparability—and gain actionable strategies to meet regulatory expectations and reduce risk.

  2. Navigating Commercial Logistics: Key Considerations For Emerging CGT Manufacturers 8/27/2025

    A successful cell and gene therapy launch requires a logistics strategy that keeps patients at the center, plans for disruptions, and prepares for future growth and global expansion.

  3. Discover The Path To Oncology Success 8/22/2025

    The oncology landscape is brimming with innovative therapies and new treatment approaches. Successful commercialization requires a well-orchestrated strategy to bring these complex products to market.

  4. Optimizing Commercial Distribution As You Prepare To Launch Your CGT 7/29/2025

    An effective commercial distribution strategy is crucial for new cell and gene therapies, helping manufacturers navigate challenges and ensure patient access.